Kaftrio May Be Effective for CF Patients With Unknown Mutation

Kaftrio May Be Effective for CF Patients With Unknown Mutation

299785

Kaftrio May Be Effective for CF Patients With Unknown Mutation

Kaftrio, marketed as Trikafta in the U.S., may be effective in people with cystic fibrosis (CF) who have one F508del mutation plus one other unknown mutation in the disease-causing gene, a study in cells taken from three such patients suggests. The results indicate that the combination therapy, which includes elexacaftor, tezacaftor, and ivacaftor, may be used to treat a broader range of CF patients. “Based on our findings, we think that the F508del/Unknown patients considered…

You must be logged in to read/download the full post.